Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026

The progressive multifocal leukoencephalopathy treatment market size has grown strongly in recent years. It will grow from $1.6 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing prevalence of immunocompromised populations, wider use of immunosuppressive therapies, improved diagnostic awareness of pml, expansion of hospital-based neurological care, availability of antiviral management protocols.

The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing research into targeted antiviral therapies, rising demand for early diagnostic tools, expansion of precision medicine approaches, growing focus on immune system modulation, increasing clinical collaborations for rare viral diseases. Major trends in the forecast period include increasing focus on immunomodulatory treatment strategies, rising use of advanced neuroimaging diagnostics, growing emphasis on early detection in immunocompromised patients, expansion of supportive and symptom management therapies, enhanced integration of multidisciplinary care teams.

The increasing prevalence of human immunodeficiency virus (HIV) infection is expected to drive the growth of the progressive multifocal leukoencephalopathy market in the coming years. HIV is a retrovirus that attacks the immune system, specifically targeting CD4 cells, also known as T cells, which are essential for the body’s ability to fight infections. Most individuals with HIV develop PML due to severe immune suppression, typically indicated by a low CD4 cell count of 200/L, which represents the most significant cause of PML cases globally. When profound HIV-related immune deficiency occurs, the latent John Cunningham virus (JCV) archetype strain in the brain can reactivate, leading to white matter lesions and the development of PML. For instance, in July 2025, according to the World Health Organization, a Switzerland-based international health organization, approximately 40.8 million people were living with HIV worldwide by the end of 2024, including 1.4 million children aged 0 to 14 years and 39.4 million adults aged 15 years and older. Therefore, the growing prevalence of HIV infection is contributing to the expansion of the progressive multifocal leukoencephalopathy market.

The rising prevalence of neurological disorders is also expected to propel the growth of the progressive multifocal leukoencephalopathy market. Neurological disorders include conditions affecting the central and peripheral nervous systems, such as the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junctions, and muscles. The increasing burden of neurological disorders is driven by factors including an aging population, genetic influences, and infectious diseases. Treatment for progressive multifocal leukoencephalopathy helps address this growing neurological burden by offering targeted therapy for PML, a severe demyelinating brain disorder, thereby reducing neurological complications and improving outcomes in immunocompromised patients. For instance, in October 2023, according to the World Federation of Neurology, a UK-based association of national neurological societies, more than 40% of the global population was experiencing some form of neurological condition, with this burden expected to nearly double by 2050. Therefore, the increasing prevalence of neurological disorders is driving growth in the progressive multifocal leukoencephalopathy market.

The expansion of research and development activities is expected to further support the growth of the progressive multifocal leukoencephalopathy treatment market going forward. Research and development activities involve rising levels of investment and effort focused on scientific investigation, experimentation, and innovation across healthcare fields. These activities are critical for improving the treatment and management of progressive multifocal leukoencephalopathy by enabling the development of more effective therapies, earlier diagnostic approaches, and improved disease management strategies. For instance, in February 2025, according to the National Center for Science and Engineering Statistics, a US-based government statistical agency, research and development spending in the United States increased from $892 billion in 2022 to $940 billion in 2023, representing a rise of $48 billion. Therefore, increasing research and development activities are driving the growth of the progressive multifocal leukoencephalopathy treatment market.

Major companies operating in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc, Johnson And Johnson, Roche Holding AG, Merck And Co Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Gilead Sciences Inc, Viatris Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Otsuka Pharmaceutical Co Ltd, Jazz Pharmaceuticals plc, Ipsen Pharma, Apotex Inc, Alkermes plc, Genentech Inc, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc, Bayer AG.

North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2025. The regions covered in the progressive multifocal leukoencephalopathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the progressive multifocal leukoencephalopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the progressive multifocal leukoencephalopathy treatment market by increasing costs of imported antiviral drugs, diagnostic imaging equipment, laboratory testing kits, and hospital-grade monitoring systems. Hospitals and specialty centers in North America and Europe are most affected due to reliance on imported pharmaceuticals and advanced diagnostics, while Asia-Pacific faces higher costs for expanding neurological care infrastructure. These tariffs are increasing treatment costs and limiting access to advanced care options. However, they are also encouraging local pharmaceutical production, regional diagnostic development, and investment in domestic infectious disease research.

The progressive multifocal leukoencephalopathy treatment market research report is one of a series of new reports that provides progressive multifocal leukoencephalopathy treatment market statistics, including progressive multifocal leukoencephalopathy treatment industry global market size, regional shares, competitors with a progressive multifocal leukoencephalopathy treatment market share, detailed progressive multifocal leukoencephalopathy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the progressive multifocal leukoencephalopathy treatment industry. This progressive multifocal leukoencephalopathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Progressive multifocal leukoencephalopathy is a rare and severe viral infection of the brain that mainly affects individuals with compromised immune systems. Treatment for this condition focuses on managing symptoms, slowing disease progression, and preventing complications, as there is currently no definitive cure and the damage caused by the virus cannot be reversed.

The primary treatment types for progressive multifocal leukoencephalopathy include antiretroviral therapy, antiviral or anti-John Cunningham virus (JCV) therapies, and others. Antiretroviral therapy involves the use of a combination of medications to treat infections caused by retroviruses, particularly the human immunodeficiency virus. These treatments are used in conditions such as HIV or AIDS, organ transplantation, multiple sclerosis, and hematologic malignancies. They can be administered through different routes, including oral and parenteral administration, and are utilized by various end users such as hospitals, homecare settings, specialty centers, and others.

The progressive multifocal leukoencephalopathy treatment market consists of revenues earned by entities by providing plasmapheresis, immune reconstitution therapy, physical therapy, supportive care, and consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The progressive multifocal leukoencephalopathy treatment market also includes sales of cidofovir, Brin cidofovir, and mefloquine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.